New gene therapies could transform sickle cell treatment forever. A future without pain crises or hospitalizations may finally be within reach.

Researchers have developed a groundbreaking AI model that identifies tumor-fighting immune cells, enhancing cancer ...

The FDA has offered positive feedback on possible paths forward for accelerated or traditional approval of FLT201 using data from a single-arm study.

Entrada plans to initiate clinical testing of ENTR-601-44 in Duchenne MD patients amenable to exon 44 skipping later this year.

Louisiana Sen. Bill Cassidy joined his Republican colleagues in voting to advance Kennedy's nomination to a vote by the full ...

The University of Southern California (USC) has received a $6m grant from the California Institute for Regenerative Medicine ...

Pluristyx, a leading provider of innovative, unmodified, and gene-edited induced pluripotent stem cell (iPSC) lines, submitted a Type II Drug Master File (DMF) to the U.S. Food and Drug Administration ...

Turnstone, which went public via an $80 million IPO in 2023, ended September 2024 with $45.3 million to hand, which the ...

AnaptysBio (NASDAQ:ANAB) stock maintained its Neutral rating and $19.00 price target from H.C. Wainwright. Currently trading ...

Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company”), a life sciences company developing precision genetic medicines for ...

H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Tenaya Therapeutics Inc (NASDAQ:TNYA), with a price target of $18.00. This aligns with the strong overall analyst consensus, as ...